Skip to main content
BRAIN Biotech AG logo

BRAIN Biotech AG — Investor Relations & Filings

Ticker · BNN ISIN · DE0005203947 LEI · 391200JKPVHLD6JLZ107 F Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2025-09-03 Board/Management Inform…
Country DE Germany
Listing F BNN

About BRAIN Biotech AG

https://www.brain-biotech.com/

BRAIN Biotech AG is an industrial biotechnology company specializing in the discovery, development, and production of specialty enzymes, high-performance microorganisms, and bioactive compounds. The company provides tailor-made biosolutions and contract research and development (R&D) services to partners in the food, chemical, and life sciences sectors. Core competencies include enzyme technology, microbial strain development, and bioprocess development. By leveraging an advanced technology portfolio, which includes proprietary platforms for enzyme discovery and genome editing, the company enables its partners to create more sustainable and efficient industrial products and processes, contributing to the bioeconomy.

Recent filings

Filing Released Lang Actions
BRAIN Biotech AG appoints Johan Jansen-Storbacka as Executive Vice President of the BRAINBiocatalysts enzyme products business
Board/Management Information Classification · 100% confidence The document is a corporate press release announcing the appointment of a new Executive Vice President at BRAIN Biotech AG. It details the personnel change, provides background on the appointee, and includes standard corporate contact information and a disclaimer. Since it focuses on a change in senior management, it falls under the 'Board/Management Information' category.
2025-09-03 English
BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts
Earnings Release Classification · 100% confidence The document is a press release announcing the financial results for the first nine months of the 2024/25 fiscal year. It provides key highlights, segment performance, and management commentary, and includes a link to the full report. According to the 'Menu vs Meal' rule, this is an announcement of financial results rather than the full interim report itself, making it an Earnings Release (ER). 9M 2025
2025-08-28 English
Q3 statement / Q3 financial report 2024/2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for BRAIN Biotech AG covering the period ending 30 June 2025. It contains detailed financial statements, including a consolidated income statement, balance sheet, cash flow statement, and selected notes to the financial statements. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2025
2025-08-28 English
Corbion and BRAIN Biotech team to shape the future of innovation in nature-based ingredient technologies
Regulatory Filings Classification · 100% confidence The document is a corporate press release announcing a strategic collaboration between Corbion and BRAIN Biotech AG. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a regulatory filing of a specific mandatory nature (like a dividend notice or director dealing). As it is a general corporate news announcement disseminated via a news service (EQS), it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements.
2025-08-25 English
Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG
Board/Management Information Classification · 100% confidence The document is a corporate news release dated July 23, 2025, announcing that an experienced biotechnology expert, Dr. Ursula La Cognata, has been appointed as a new member of the Supervisory Board of BRAIN Biotech AG. This content directly relates to changes in the company's board of directors or senior management structure. This aligns perfectly with the definition for Board/Management Information (MANG). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2025-07-23 English
Price range set: Brainlab targets a market capitalization of c. EUR 1.67 billion to EUR 2.09 billion
Capital/Financing Update Classification · 98% confidence The document is a press release dated June 23, 2025, announcing that Brainlab AG has set the price range for its planned Initial Public Offering (IPO). Key phrases include 'Price range set', 'planned initial public offering', 'capital increase', 'secondary shares', and details about the expected first day of trading on the Frankfurt Stock Exchange (Prime Standard). This content directly relates to fundraising, capital structure changes, and the issuance of new shares to the public. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). While it involves share issuance (SHA), the primary focus is the financing event (IPO pricing and proceeds) rather than just a general share change announcement. It is not a full prospectus, nor is it a simple announcement of a report (RPA/RNS), as it contains substantive financial/transactional details about the offering itself.
2025-06-23 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.